FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206587> ?p ?o ?g. }

• W4387206587 endingPage "e414" @default.
• W4387206587 startingPage "e414" @default.
• W4387206587 abstract "The combination of short-term androgen deprivation therapy (ST-ADT) with prostate radiotherapy (RT) is a standard of care for patients with localized prostate cancer (LPCa). After cessation of ST-ADT, it takes about 8 to 10 months for the testosterone (T) to recover to supracastrate levels, which could drive changes in PSA kinetics. It largely remains unknown whether early changes in PSA kinetics after T recovery could predict for subsequent biochemical relapse.We performed a secondary analysis of a phase III randomized controlled trial in which patients with newly diagnosed LPCa with Gleason score £7, clinical stage T1b to T3a, and PSA <30 ng/mL were randomly allocated to neoadjuvant and concurrent ADT for 6 months starting 4 months before prostate RT (76 Gy in 38 fractions over 7.5 weeks) or concurrent and adjuvant ADT for 6 months starting simultaneously with prostate RT. Clinical assessment and laboratory investigations were repeated 1 month after completion of ADT, every 4 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter. We calculated the PSA doubling time (PSADT) based on PSA values up to 18 months after recovery of T to a supracastrate level (>50 ng/dL). Patients with ³3 PSA measurements after T recovery to supracastrate level were included in this analysis. Fine and Gray cumulative incidence of biochemical recurrence (BCR) was calculated in patients with PSADT at or above median versus below median. Deaths were considered as competing events. All endpoints were calculated from the time of T recovery to supracastrate level. Subdistribution hazard ratios (sHR) with 95% confidence intervals (CI) were estimated for association of PSADT with relative incidence of recurrence using competing risk regression after adjusting for tumor stage, pre-treatment PSA, Gleason score, treatment regimen, and age at randomization.Overall, 311 patients were eligible for this analysis. Median PSADT was 8 months. Cumulative incidence of BCR at 10 years was 31.0% and 20.7% in patients with PSADT <8 months and ³8 months, respectively. Longer PSADT was associated with a significantly lower risk of cumulative incidence of BCR (sHR for PSADT as a continuous variable 0.43, 95% CI: 0.28-0.66; sHR for PSADT ³8 months 0.54, 95% CI: 0.30-0.99). After adjustment for time to recovery of T to supracastrate level in addition to the aforementioned variables, longer PSADT (³8 months) was associated with lower risk of cumulative incidence of BCR (sHR: 0.53, 95% CI: 0.27-1.01).These findings suggest that early PSA kinetics within 18 months of recovery of T to a supracastrate level predict for subsequent biochemical failure. Taking account of early changes in PSA after testosterone recovery may allow for recognition of potential failures earlier in the disease course and thereby permit greater personalization of management decisions." @default.
• W4387206587 created "2023-09-30" @default.
• W4387206587 creator A5014871240 @default.
• W4387206587 creator A5027101830 @default.
• W4387206587 creator A5041615709 @default.
• W4387206587 creator A5043559301 @default.
• W4387206587 creator A5058146963 @default.
• W4387206587 creator A5070757819 @default.
• W4387206587 creator A5075361012 @default.
• W4387206587 creator A5076213753 @default.
• W4387206587 creator A5082004047 @default.
• W4387206587 creator A5089565249 @default.
• W4387206587 date "2023-10-01" @default.
• W4387206587 modified "2023-10-04" @default.
• W4387206587 title "Association of Prostate Specific Antigen Kinetics after Testosterone Recovery with Subsequent Recurrence: Secondary Analysis of a Phase III Randomized Controlled Trial" @default.
• W4387206587 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1562" @default.
• W4387206587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785369" @default.
• W4387206587 hasPublicationYear "2023" @default.
• W4387206587 type Work @default.
• W4387206587 citedByCount "0" @default.
• W4387206587 crossrefType "journal-article" @default.
• W4387206587 hasAuthorship W4387206587A5014871240 @default.
• W4387206587 hasAuthorship W4387206587A5027101830 @default.
• W4387206587 hasAuthorship W4387206587A5041615709 @default.
• W4387206587 hasAuthorship W4387206587A5043559301 @default.
• W4387206587 hasAuthorship W4387206587A5058146963 @default.
• W4387206587 hasAuthorship W4387206587A5070757819 @default.
• W4387206587 hasAuthorship W4387206587A5075361012 @default.
• W4387206587 hasAuthorship W4387206587A5076213753 @default.
• W4387206587 hasAuthorship W4387206587A5082004047 @default.
• W4387206587 hasAuthorship W4387206587A5089565249 @default.
• W4387206587 hasConcept C121608353 @default.
• W4387206587 hasConcept C126322002 @default.
• W4387206587 hasConcept C126894567 @default.
• W4387206587 hasConcept C141071460 @default.
• W4387206587 hasConcept C168563851 @default.
• W4387206587 hasConcept C203092338 @default.
• W4387206587 hasConcept C2776235491 @default.
• W4387206587 hasConcept C2777008409 @default.
• W4387206587 hasConcept C2777899217 @default.
• W4387206587 hasConcept C2779279991 @default.
• W4387206587 hasConcept C2779466945 @default.
• W4387206587 hasConcept C2780192828 @default.
• W4387206587 hasConcept C2781406297 @default.
• W4387206587 hasConcept C509974204 @default.
• W4387206587 hasConcept C71924100 @default.
• W4387206587 hasConceptScore W4387206587C121608353 @default.
• W4387206587 hasConceptScore W4387206587C126322002 @default.
• W4387206587 hasConceptScore W4387206587C126894567 @default.
• W4387206587 hasConceptScore W4387206587C141071460 @default.
• W4387206587 hasConceptScore W4387206587C168563851 @default.
• W4387206587 hasConceptScore W4387206587C203092338 @default.
• W4387206587 hasConceptScore W4387206587C2776235491 @default.
• W4387206587 hasConceptScore W4387206587C2777008409 @default.
• W4387206587 hasConceptScore W4387206587C2777899217 @default.
• W4387206587 hasConceptScore W4387206587C2779279991 @default.
• W4387206587 hasConceptScore W4387206587C2779466945 @default.
• W4387206587 hasConceptScore W4387206587C2780192828 @default.
• W4387206587 hasConceptScore W4387206587C2781406297 @default.
• W4387206587 hasConceptScore W4387206587C509974204 @default.
• W4387206587 hasConceptScore W4387206587C71924100 @default.
• W4387206587 hasIssue "2" @default.
• W4387206587 hasLocation W43872065871 @default.
• W4387206587 hasLocation W43872065872 @default.
• W4387206587 hasOpenAccess W4387206587 @default.
• W4387206587 hasPrimaryLocation W43872065871 @default.
• W4387206587 hasRelatedWork W1980188241 @default.
• W4387206587 hasRelatedWork W1992657261 @default.
• W4387206587 hasRelatedWork W2038565121 @default.
• W4387206587 hasRelatedWork W2127440557 @default.
• W4387206587 hasRelatedWork W2148869351 @default.
• W4387206587 hasRelatedWork W2373651588 @default.
• W4387206587 hasRelatedWork W2897445903 @default.
• W4387206587 hasRelatedWork W3129209394 @default.
• W4387206587 hasRelatedWork W3163649103 @default.
• W4387206587 hasRelatedWork W4281788288 @default.
• W4387206587 hasVolume "117" @default.
• W4387206587 isParatext "false" @default.
• W4387206587 isRetracted "false" @default.
• W4387206587 workType "article" @default.